Blockchain Registration Transaction Record

Kidney Disease Research Leader Dr. Katherine Tuttle to Receive 2026 AHA Clinical Research Prize

Dr. Katherine Tuttle to receive AHA's 2026 Clinical Research Prize for transforming chronic kidney disease and cardiovascular-kidney-metabolic care.

This recognition underscores the critical link between kidney disease and cardiovascular health, highlighting how integrated approaches to cardiovascular-kidney-metabolic (CKM) syndrome can save lives. Dr. Tuttle's pioneering research on SGLT2 inhibitors and GLP-1 receptor agonists has already transformed treatment paradigms, offering new hope for millions living with chronic kidney disease and diabetes. As CKM syndrome gains global attention, her work paves the way for more personalized, effective therapies that address the interconnected nature of these conditions. The award not only honors her lifetime of achievement but also signals a broader shift in medicine toward holistic, patient-centered care that considers the heart, kidneys, and metabolic system as one.